Screening tests are laboratory tests that help to identify people at increased risk for a condition or disease before they have symptoms or even realize they may be at risk so that preventive measures can be taken. Screening tests help detect disease in its earliest and most treatable stages. They should be sensitive – that is, to correctly identify those individuals who have a given disease. Many routine tests performed at regular health exams are screening tests such as Cholesterol testing and Pap smears for women. Newborns are screened for a variety of conditions at birth.
InSure® FIT™ is a CLIA waived test that is available for Physician Office Lab (POL) testing. To help improve
colorectal cancer screening compliance, InSure®FIT™ screening test offers high sensitivity and ease of use. It is a highly patient-friendly water-Based collection method. It’s patented brush sampling replaces unpleasant fecal collection or smearing and there are no dietary or medication restrictions. InSure® FIT™ has 87% sensitivity for colorectal cancer & 98% specificity. The test has a 66% increase in patient compliance versus a guaiac-based fecal occult blood test (gFOBT) based on a recent study1.
New Born Screening (NBS)
Newborn screening identifies babies with treatable congenital disorders to prevent adverse outcomes. All of the disorders on the newborn screening panel can be detected by a blood spot collected on filter paper after 24 hours but within 48 hours of birth.